In English | En español
Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Featured Trials

Thyroid Cancer - Featured Clinical Trials

The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:

  • Testing Vascular Disruption Combined with Chemotherapy for Advanced Solid Tumors
    (Posted: 04/17/2012) - In this phase I/II trial, doctors will assess the safety and tolerability of intravenous crolibulin and cisplatin in patients with advanced solid tumors, establish the maximum tolerated dose for the combination, and randomly assign patients with anaplastic thyroid cancer to receive crolibulin and cisplatin or cisplatin alone.
  • Exploring the Anticancer Potential of Valproic Acid in Advanced Thyroid Cancer
    (Posted: 03/07/2012) - In this trial, patients with advanced thyroid cancers of follicular cell origin whose tumors are not sensitive to radioactive iodine therapy will take valproic acid for 10 weeks and then undergo a radioactive iodine uptake test.
  • New Drug for Patients with Advanced Thyroid Cancer
    (Posted: 11/18/2008) - In this phase II trial, researchers are studying the effects of treatment with 17-AAG, an antitumor antibiotic drug that targets a protein called HSP90, in patients with advanced medullary or differentiated thyroid cancer.
  • Treating Hereditary Thyroid Cancer in Children
    (Posted: 12/18/2007) - In this clinical trial, doctors are testing a new drug called vandetanib (Zactima) in young patients with advanced hereditary medullary thyroid cancer. Vandetanib targets the specific genetic defect responsible for these tumors.
  • Targeted Combination Therapy for Advanced Solid Tumors
    (Posted: 07/19/2005) - In this study, researchers are assessing the safety and combined effectiveness of bevacizumab and a second drug called sorafenib. Both bevacizumab and sorafenib inhibit the formation of blood vessels to tumors and may act synergistically when combined.